These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27760936)

  • 1. [Clinical Experience of Ramucirumab for Treating Advanced Gastric Cancer].
    Kimura Y; Makari Y; Mikami J; Kamigaki S; Ikejima A; Fujii C; Sawada G; Nakahira S; Yamamura J; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1193-1196. PubMed ID: 27760936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Clinical Effect of Ramucirumab in the Treatment of Advanced Gastric Cancer in Our Hospital].
    Kenno S; Takahashi S; Noguchi K; Yamagami H; Ishizu H; Takahashi M
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):79-81. PubMed ID: 29362314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
    BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
    Kimura M; Usami E; Teramachi H; Yoshimura T
    J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
    Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy].
    Kimura Y; Makari Y; Mikami J; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Fujita J; Furukawa H; Yasuda T
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1080-1082. PubMed ID: 29394540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and Safety of Paclitaxel plus Ramucirumab Therapy for Unresectable or Recurrent Gastric Cancer].
    Tsujio G; Toyokawa T; Fukuoka T; Tamura T; Ohira G; Shibutani M; Yamazoe S; Nagahara H; Kimura K; Amano R; Tanaka H; Muguruma K; Yashiro M; Maeda K; Hirakawa K; Ohira M
    Gan To Kagaku Ryoho; 2019 May; 46(5):895-899. PubMed ID: 31189811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
    Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
    Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A Case of an Elderly Patient with Unresectable Gastric Cancer Treated by Paclitaxel and Ramucirumab].
    Kimura Y; Makari Y; Mikami J; Yoshimura J; Inoue T; Sawada G; Nakahira S; Yamamura J; Kamigaki S; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2404-2406. PubMed ID: 28133336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Three Patients with Gastric Cancer Who Underwent Surgery during Ramucirumab Treatment].
    Omori H; Kawai S; Makuuchi R; Irino T; Tokunaga M; Tanizawa Y; Bando E; Kawamura T; Yasui H; Terashima M
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):1021-1023. PubMed ID: 29138380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial.
    Sato Y; Yamashita H; Yagi K; Nomura S; Seto Y
    Anticancer Res; 2024 Jul; 44(7):3125-3131. PubMed ID: 38925825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
    Zhang X; Zhou L; Zhou C; Shen L
    Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
    Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy.
    Kakuta T; Yabusaki H; Bamba T; Aizawa M; Nogami H; Nomura T; Matsuki A; Maruyama S; Takii Y; Nakagawa S
    Int J Clin Oncol; 2021 Apr; 26(4):684-693. PubMed ID: 33389346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study.
    Negoro Y; Maeda T; Igarashi H; Shigemori M; Tanaka T; Ito Y; Tanizawa N; Nishikawa S; Ogawa J; Kamitani Y; Watanabe K; Tsukamoto H; Goto N
    Support Care Cancer; 2024 Oct; 32(10):704. PubMed ID: 39370483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Locally Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy with Ramucirumab plus Paclitaxel-Case Report].
    Matsui H; Shimizu Y; Tachikawa H; Homma T; Mizukami T; Hashimoto T; Abe H
    Gan To Kagaku Ryoho; 2019 Oct; 46(10):1565-1567. PubMed ID: 31631140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
    Natsume M; Shimura T; Iwasaki H; Okuda Y; Kitagawa M; Okamoto Y; Hayashi K; Kataoka H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1037-1046. PubMed ID: 30899983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals.
    Hashida S; Tanaka N; Takahashi Y; Onoda Y; Colvin HS; Ohashi R; Okamoto K
    Acta Med Okayama; 2021 Apr; 75(2):133-138. PubMed ID: 33953419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
    Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
    J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.